Anemia - pernicious
Methodology & AI Transparency ⓘ
Anemia - pernicious Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Physicians managing Anemia - pernicious (D51.0; Anemia, Clotting & Blood Disorders) utilize B12/MMA/folate [Anemia - pernicious D51.0] and objective Vitamin B12, Folate in Anemia - pernicious (D51.0: & Reticulocyte Count) targets (B12 > 500 pg/mL; appropriate marrow response (D51.0)) to prevent progression and functional morbidity.
- 2 Real-world patient consensus: Mapped to Anemia, Clotting & Blood Disorders under ICD-10-CM D51.0 for Anemia - pernicious clinical workups.
- 3 Typical cash cost range: Clinicians assessing Anemia - pernicious focus on or folate deficiency [Anemia - pernicious D51.0] and targeted history.
- 4 Top reported side effects / signs: Objective lab/clinical target for Anemia - pernicious: Vitamin B12, Folate in Anemia - pernicious (D51.0: & Reticulocyte Count) (B12 > 500 pg/mL; appropriate marrow response (D51.0)) and Platelet Count & in Anemia - pernicious (D51.0: PT/INR / aPTT).
Ask our AI Specialists anything about Anemia - pernicious
What Is Anemia - pernicious?
Physicians managing Anemia - pernicious (D51.0; Anemia, Clotting & Blood Disorders) utilize B12/MMA/folate [Anemia - pernicious D51.0] and objective Vitamin B12, Folate in Anemia - pernicious (D51.0: & Reticulocyte Count) targets (B12 > 500 pg/mL; appropriate marrow response (D51.0)) to prevent progression and functional morbidity.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Anemia - pernicious (ICD-10 D51.0) is driven by or folate deficiency [Anemia - pernicious D51.0]; specialists in Anemia, Clotting & Blood Disorders monitor Platelet Count & in Anemia - pernicious (D51.0: PT/INR / aPTT) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Anemia - pernicious (D51.0): easy bruising, prolonged in Anemia - pernicious (D51.0: bleeding from minor)
- • Secondary Anemia - pernicious clinical sign: unexplained limb swelling/clotting in Anemia - pernicious (D51.0: tendency or recurrent)
- • Symptom flares in Anemia - pernicious correlating with Vitamin B12, Folate in Anemia - pernicious (D51.0: & Reticulocyte Count) deviation outside B12 > 500 pg/mL; appropriate marrow response (D51.0)
- • Functional blood & anemia impact requiring B12/MMA/folate [Anemia - pernicious D51.0] evaluation (D51.0)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Anemia - pernicious Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | D51.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Anemia, Clotting & Blood Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Vitamin B12, Folate in Anemia - pernicious (D51.0: & Reticulocyte Count) | B12 > 500 pg/mL; appropriate marrow response (D51.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Platelet Count & in Anemia - pernicious (D51.0: PT/INR / aPTT) | Platelets 150–400 x10^3/uL (D51.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Hemoglobin, Hematocrit & in Anemia - pernicious (D51.0: MCV) | Hgb 13.5–17.0 (M) / 12.0–15.5 (F) g/dL (D51.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Anemia - pernicious
Treatment selection for Anemia - pernicious depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Anemia - pernicious)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Efficacy of Testosterone Replacement Therapy in Correcting Anemia in Men With: What a 5,204-Participant Study Found A total of 5204 men were included, 815 with anemia (mean [SD] age, 64.8 [7.7] years; 247 Black [30.3%], 544 White [66.7%], 24 other [2.9%]) and 4379 without anemia (mean [SD] age, 63.0 [7.9] years; 629 Black [14.4%], 3603... JAMA network open • 2023-10-02 • Randomized Controlled Trial | N = 5,204 | 96/100 | PMID 37889486 ↗ |
| New Insights on Roxadustat for the treatment of anemia in chronic kidney disease patients not on: What a 594-Participant Study Found Roxadustat demonstrated superior efficacy versus placebo in terms of both Hb response rate and change in Hb from BL. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association • 2021-08-27 • Phase III Randomized Trial | N = 594 | 93/100 | PMID 33630072 ↗ |
| New Insights on Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic: What a 1,068-Participant Study Found Roxadustat effectively increased hemoglobin in patients with DD-CKD, with an AE profile comparable to epoetin alfa. Journal of the American Society of Nephrology : JASN • 2022-04-15 • Phase III Randomized Trial | N = 1,068 | 90/100 | PMID 35361724 ↗ |
| Living Longer With Bone Marrow Scarring: What 2,233 Patients Taught Doctors About Ruxolitinib Results support use of anemia-supporting medications with ruxolitinib and may allow maintenance of ruxolitinib dose intensity in patients with myelofibrosis and anemia. Hematology (Amsterdam, Netherlands) • 2026-12-31 • Phase III Randomized Trial | N = 2,233 | 90/100 | PMID 42698151 ↗ |
| New Insights on Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with: What a 2,142-Participant Study Found There was no evidence of increased risk of heart and blood vessel events or mortality with roxadustat compared with ESA in patients with anemia who have NDD or ID-DD CKD. Advances in therapy • 2023-04-15 • Phase III Randomized Trial | N = 2,142 | 90/100 | PMID 36749544 ↗ |
Anemia - pernicious Patient Community & “People Like Me” Threads
Filter Anemia - pernicious community threads and patient logs by age, biological sex, dosage, and treatment duration.